DUBLIN–(BUSINESS WIRE)–The “Global Joint Venture Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2014-2020” report has been added to ResearchAndMarkets.com’s offering.
The Global Joint Venture Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2014-2020 report provides comprehensive understanding and unprecedented access to the joint venture deals and agreements entered into by the worlds leading life science companies.
This report provides details of the latest joint venture agreements announced in the pharmaceutical, biotechnology and diagnostic sectors. Fully up to date, the report provides details of joint venture agreements from 2014. There is an increasing willingness for parties to enter joint venture deals; such deals enable both parties to benefit from the upside of a big product win, whereas traditional licensing deals forfeit upside for near term upfront, milestone and royalty payments.
This report contains a comprehensive listing of all joint venture deals announced since 2014 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual joint venture contract documents as submitted to the Securities Exchange Commission by companies and their partners.
Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.
Key benefits of the report:
- In-depth understanding of joint venture partnering deal trends since 2014
- Analysis of the structure of joint venture agreements with numerous real life case studies
- Comprehensive listing of all joint venture deals since 2014, together with deal terms, value and press release
- Comprehensive access to actual joint venture contracts entered into by the world’s life science companies
- Insight into the terms included in a joint venture agreement, together with real world clause examples
- Understand the key deal terms companies have agreed in previous deals
- Undertake due diligence to assess suitability of your proposed deal terms for partner companies
Key Topics Covered:
Chapter 1 – Introduction
Chapter 2 – Trends in joint venture partnerships
2.1. Introduction
2.2. Definition of joint venture deals
2.3. Success factors for joint venture partnerships
2.4. When joint venture partnerships can be useful
2.5. Attributes of joint venture partnerships
2.6. Aligning partners to make the joint venture work
2.7. Trends in joint venture partnerships since 2014
2.7.1. Joint venture dealmaking by year, 2014 to 2020
2.7.2. Joint venture dealmaking by stage of development 2014 to 2020
2.7.3. Joint venture dealmaking by industry sector 2014 to 2020
2.7.4. Joint venture dealmaking by therapy area, 2014 to 2020
2.7.5. Joint venture dealmaking by technology type, 2014 to 2020
2.7.6. Joint venture dealmaking by most active company, 2014 to 2020
2.8. The future of joint venture partnerships
Chapter 3 – Overview of joint venture deal structure
3.1. Introduction
3.2. Joint venture agreement structure
3.3. Example joint venture agreements
3.3.1. Case study 1: Agila Specialties – Pfenex
3.3.2. Case study 2: Dance Biopharm – Harmony Asset
Chapter 4 – Leading joint venture deals
4.1. Introduction
4.2. Top joint venture deals by value
Chapter 5 – Top 25 most active joint venture dealmakers
5.1. Introduction
5.2. Top 25 most active joint venture dealmakers
Chapter 6 – Joint venture deals including contracts directory
6.1. Introduction
6.2. Joint venture deals with contracts 2014 to 2020
Companies Mentioned
- 3SBio
- 1717 Life Science Ventures
- A*STAR Agency for Science
- Technology and Research
- A*STAR Institute of Microelectronics (IME)
- A*STAR’ Institute of Molecular and Cell Biology
- A2A Pharmaceuticals
- AAP Implantate AG
- Abbott Laboratories
- Abbvie
- Abilita Bio
- ABIVAX
- Abzena
- Accellix
- Accuray
- Acnos Pharma
- Adept Neuro
- Adisseo
- Advanced Prenatal Therapeutics
- Advanced Technologies Solutions
- Aequus Pharmaceuticals
- Agilis Biotherapeutics
- AgonOx
- AirWare Labs
- Aitbiotech
- Akers Biosciences
- AKESOgen
- Aleafia Health
- Aleva Neurotherapeutics
- Allied-Bristol Life Sciences
- Allied Minds
- Ally Bridge Group
- Altus Formulation
- Alzheimer’s Association
- Alzheimer’s Research UK
- Amarantus BioSciences
- Amendia
- American Diabetes Association
- AmerisourceBergen
- Amunix
- Amyris
- AnaBios
- Anokion
- Antitope
- Antoxerene
- Apax Partners
- Aphria
- Arbele
- Arbutus
-
And Many Many More Companies!
For more information about this report visit https://www.researchandmarkets.com/r/f9spa8
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900